SEPTIN9 Gene Methylation Ratio as Follow‐Up Biomarker in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Authors:
- Víctor Domínguez‐PrietoVDVíctor Domínguez‐Prieto
- Rocío Olivera‐SalazarRORocío Olivera‐Salazar
- Miguel León‐ArellanoMLMiguel León‐Arellano
- Luz Vega‐ClementeLVLuz Vega‐Clemente
- Rocío Barrueco‐GutiérrezRBRocío Barrueco‐Gutiérrez
- Cristina CaramésCCCristina Caramés
- Eva Ruiz‐HispánEREva Ruiz‐Hispán
- Raquel Fuentes‐MateosRFRaquel Fuentes‐Mateos
- Diana Isabel Rosero‐RodríguezDRDiana Isabel Rosero‐Rodríguez
- Ignacio Mahillo‐FernándezIMIgnacio Mahillo‐Fernández
- Héctor GuadalajaraHéctor Guadalajara
- Mariano García‐ArranzMGMariano García‐Arranz
- 29 July 2026
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (6) , 822-829
Abstract
Background: There are not reliable biomarkers for the assessment of tumor response to total neoadjuvant therapy (TNT) and the early detection of local regrowth or systemic relapse in patients with locally advanced rectal cancer (LARC). Our aim is to evaluate the utility of SEPTIN9 methylation ratio (SEPT9mr) for prediction and assessment of tumor response to TNT and for early diagnosis of local regrowth and systemic metastases in patients with LARC. Methods: Patients with LARC undergoing TNT were prospectively included. SEPTIN9 methylation status gene in plasmatic cfDNA was determined by ddPCR and expressed as SEPT9mr at 3 times: pre‐treatment, evaluation of tumor response and follow‐up. Association between pre‐treatment SEPT9mr, tumor response to TNT and metastatic risk was explored. Association between SEPT9mr variation between samples and tumor response to TNT, local regrowth and systemic metastases was also explored. Results: Sixty patients were included. Pre‐treatment SEPT9mr ( p = 0.004) significantly associated with tumor response to TNT, but not with metastatic risk during follow‐up ( p = 0.289). Variation of SEPT9mr during TNT did not significantly associate with tumor response to TNT ( p = 0.130). Variation of SEPT9mr during follow‐up did not associate with the development of local regrowth ( p = 0.533) but significantly associated with the development of systemic metastases ( p = 0.026). Conclusion: Pre‐treatment SEPT9mr can predict tumor response to TNT, but not the metastatic risk during follow‐up. Variation of SEPT9mr between samples seems to be useful for early detection of systemic metastases during follow‐up but not for evaluation of tumor response to TNT or detection of local regrowth.Keywords
Funding Information
- European Regional Development Fund
This publication has 26 references indexed in Scilit:
- Total neoadjuvant therapy in rectal cancer: the evidence and expectationsCritical Reviews in Oncology/Hematology, 2023
- Aging: Epigenetic modifications2023
- Metastatic colorectal cancer: mechanisms and emerging therapeuticsTrends in Pharmacological Sciences, 2023
- Modest agreement between magnetic resonance and pathological tumor regression after neoadjuvant therapy for rectal cancer in the real worldInternational Journal of Cancer, 2022
- Quality of life after sphincter preservation surgery or abdominoperineal resection for low rectal cancer (ASPIRE): A long-term prospective, multicentre, cohort studyThe Lancet Regional Health - Western Pacific, 2021
- Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal CancerJAMA Network Open, 2020
- Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal CancerJAMA Oncology, 2018
- Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancerBritish Journal of Cancer, 2017
- The Role of DNA Methylation in Aging, Rejuvenation, and Age-Related DiseaseRejuvenation Research, 2012
- Preoperative versus Postoperative Chemoradiotherapy for Rectal CancerNew England Journal of Medicine, 2004